Midregional pro-atrial natriuretic peptide and outcome in patients with acute ischemic stroke

What Was Tested

This clinical trial paper looks at ANP (Atrial Natriuretic Peptide).

The purpose of this study was to examine the prognostic value of midregional pro-atrial natriuretic peptide (MR-proANP) in patients with acute ischemic stroke.

Why It Was Studied

The rapid and reliable estimation of prognosis in acute ischemic stroke is pivotal to optimize clinical care.

MR-proANP, a recently described, stable fragment of the ANP precursor hormone, may be useful in this setting.

Who Took Part

The abstract describes 362 patients taking part.

The age groups tagged for this paper are middle-aged adults, older adults and people over 80, both men and women.

In a prospective observational study, the researchers measured MR-proANP on admission in plasma of 362 consecutive patients presenting with acute ischemic stroke.

How the Study Was Run

The timeline in the abstract includes 90 days.

The prognostic value of MR-proANP to predict mortality within 90 days and functional outcome (defined as a modified Rankin Scale of ≤2 or ≥3) was evaluated and compared with the National Institutes of Health Stroke Scale (NIHSS) score.

What Was Measured

Topics PubMed links to this paper include Atrial Natriuretic Factor, Biomarkers, Brain Ischemia, Outcome Assessment, Health Care, Predictive Value of Tests, Prognosis and Stroke.

What This Means in Plain Language

This is a clinical trial of ANP (Atrial Natriuretic Peptide) in 362 patients over 90 days.

With several hundred people or more, it is a fairly large study for this kind of research.

Results are reported in around 7 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2010 (Journal of the American College of Cardiology), a journal based in United States.

More context: the ANP (Atrial Natriuretic Peptide) compound page, all human trials.